Jefferies Group's FATE Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 59,122 shares of Fate Therapeutics, Inc. (FATE) worth $159,629, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Jefferies Group has initiated a new position in FATE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Fate Therapeutics (FATE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Fate Therapeutics (FATE) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +59,122 | New Buy | 59,122 | $2.70 |
Jefferies Group's Fate Therapeutics Investment FAQs
Jefferies Group first purchased Fate Therapeutics, Inc. (FATE) in Q2 2026, acquiring 59,122 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Fate Therapeutics, Inc. (FATE) for 1 quarters since Q2 2026.
Jefferies Group's largest addition to Fate Therapeutics, Inc. (FATE) was in Q2 2026, adding 59,122 shares worth $159,629.
According to the latest 13F filing for Q2 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 59,122 shares of Fate Therapeutics, Inc. (FATE), valued at approximately $159,629.
As of the Q2 2026 filing, Fate Therapeutics, Inc. (FATE) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Fate Therapeutics, Inc. (FATE) was 59,122 shares, as reported at the end of Q2 2026.